Boston, Massachusetts, United States Kestrel Management is the famous Corporate Investor, which was founded in 1998. The main office of represented Corporate Investor is situated in the Boston. The venture was found in North America in United States.
The fund is generally included in less than 2 deals every year. The top activity for fund was in 2003. Deals in the range of 10 - 50 millions dollars are the general things for fund. The top amount of exits for fund were in 2008.
We also calculated 2 valuable employees in our database.
Among the most popular portfolio startups of the fund, we may highlight Xanthus Pharmaceuticals. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. We can highlight the next thriving fund investment areas, such as Software, SaaS. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund.
The usual cause for the fund is to invest in rounds with 8-9 partakers. Despite the Kestrel Management, startups are often financed by The Still River Fund, Kestrel Venture Management, HealthCare Ventures. The meaningful sponsors for the fund in investment in the same round are Yasuda Enterprise Development, The Still River Fund, Oxford Bioscience Partners. In the next rounds fund is usually obtained by Yasuda Enterprise Development, The Still River Fund, Neomed Management.
Related Funds
| Fund Name | Location |
| Austin Rief Ventures | - |
| Delta Northern Rivers Fund | - |
| John Crane | Illinois, Morton Grove, United States |
| Jolly Capital | China, Shanghai |
| MUFG Bank | Chiyoda, Japan |
| Shuidishi Fund | - |
| Sichuan Runheng | Chengdu, China, Sichuan |
| Wellstreet | Stockholm, Stockholm County, Sweden |
| Zhangxin Qubao | China, Guangdong Province, Longgang District |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
jiritsu.network | $10M | 19 Sep 2023 | - | ||
Xanthus Pharmaceuticals | $30M | 12 Dec 2003 | Cambridge, Massachusetts, United States | ||
CardioFocus | $1M | 02 Aug 2001 | Marlborough, Massachusetts, United States | ||
CardioFocus | $9M | 06 Jan 2000 | Marlborough, Massachusetts, United States | ||
CardioFocus | $2M | 01 Aug 1998 | Marlborough, Massachusetts, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
jiritsu.network | $10M | 19 Sep 2023 | - | ||
Xanthus Pharmaceuticals | $30M | 12 Dec 2003 | Cambridge, Massachusetts, United States | ||
CardioFocus | $1M | 02 Aug 2001 | Marlborough, Massachusetts, United States | ||
CardioFocus | $9M | 06 Jan 2000 | Marlborough, Massachusetts, United States | ||
CardioFocus | $2M | 01 Aug 1998 | Marlborough, Massachusetts, United States |
